Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -96.72% | 284.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -96.72% | 284.16% | |||
| Cost of Revenue | 35.90% | 129.70% | |||
| Gross Profit | -303.81% | -83.12% | |||
| SG&A Expenses | 5.59% | 5.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 23.23% | 9.00% | |||
| Operating Income | -2,564.66% | 93.26% | |||
| Income Before Tax | -2,946.50% | 93.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,946.50% | 93.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,946.50% | 93.28% | |||
| EBIT | -2,564.66% | 93.26% | |||
| EBITDA | -2,883.97% | 93.96% | |||
| EPS Basic | -2,692.31% | 93.91% | |||
| Normalized Basic EPS | -2,350.00% | 94.01% | |||
| EPS Diluted | -2,692.31% | 93.91% | |||
| Normalized Diluted EPS | -2,350.00% | 94.01% | |||
| Average Basic Shares Outstanding | 9.35% | 10.13% | |||
| Average Diluted Shares Outstanding | 9.35% | 10.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||